Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPC


Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

Olivier Elemento, PhD, professor, Physiology and Biophysics, Walter B. Wriston Research Scholar, professor, Computational Genomics, Computational Biomedicine, associate director, the Institute for Computational Biomedicine, Weill Cornell Medicine, Physiology and Biophysics, director, the Englander Institute, Precision Medicine Associate, director, the Institute for Computational Biomedicine, discusses utilizing circulating tumor cells (CTCs) to assess treatment resistance in metastatic castration-resistant prostate cancer (mCRPC).

The detection of an inflammatory response signature in CTCs was found to be associated with acquired antiandrogen resistance, Elemento says. Moreover, examining the transcriptome of immune cells in the blood showed that an enrichment of gene signatures, such as the inflammasome gene signature, served as another indicator of progression, Elemento explains

The detection and change of these signatures at various points of disease can help predict progression, making it important to evaluate these signatures at diagnosis, Elemento continues. This research could help indicate if a change in expression of gene signatures are correlated with progression, which could assist in preventing progression in the future, Elemento continues. Leveraging CTCs at baseline could serve as an earlier indicator of which patients are more likely to progress, and these data could drive treatment decisions in patients to potentially prevent progression, Elemento concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD